Literature DB >> 20337973

Glucokinase diabetes in 103 families from a country-based study in the Czech Republic: geographically restricted distribution of two prevalent GCK mutations.

Stepanka Pruhova1, Petra Dusatkova, Zdenek Sumnik, Stanislava Kolouskova, Oluf Pedersen, Torben Hansen, Ondrej Cinek, Jan Lebl.   

Abstract

BACKGROUND: Glucokinase diabetes, also called GCK-MODY or maturity-onset diabetes of the young type 2 (MODY2), is caused by heterozygous mutations in the gene encoding glucokinase (GCK).
OBJECTIVE: The aim of study was to investigate the current prevalence of GCK mutations in a large cohort of Czech patients with typical clinical appearance of GCK-MODY. In addition, we reanalyzed the negative results obtained previously by screening using the denaturing high-performance liquid chromatography (dHPLC).
METHODS: We studied 140 unrelated Czech probands with clinical picture of GCK-MODY who were referred to our center from the whole of the Czech Republic between the years 1999-2009 by direct sequencing of GCK gene.
RESULTS: A mutation in GCK was identified in 103 of 140 probands (74%). We identified 46 different GCK mutations of which 13 were novel. Several mutations were detected in multiple families: p.Glu40Lys (20 families), p.Gly318Arg (12), p.Leu315His (7) and p.Val33Ala (six families). Direct sequencing detected a GCK mutations in 9 of 20 previously dHPLC-negative samples; the sensitivity of the dHPLC screening was calculated as 84%.
CONCLUSIONS: The study shows a relatively high proportion of GCK mutations among individuals with GCK-like phenotype, confirming the effectiveness of carefully applied clinical criteria prior to genetic testing. In the Czech MODY registry, GCK-MODY represents the biggest subgroup of MODY (35%). We report several prevalent GCK mutations with a likely founder effect in the Czech population. Furthermore, our results provide ground for a possible recommendation to reinspect all negative results previously obtained by screening using dHPLC.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20337973     DOI: 10.1111/j.1399-5448.2010.00646.x

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  10 in total

1.  Maturity-onset diabetes of the young in a large Portuguese cohort.

Authors:  Sílvia Santos Monteiro; Tiago da Silva Santos; Liliana Fonseca; Guilherme Assunção; Ana M Lopes; Diana B Duarte; Ana Rita Soares; Francisco Laranjeira; Isaura Ribeiro; Eugénia Pinto; Sónia Rocha; Sofia Barbosa Gouveia; María Eugenia Vazquez-Mosquera; Maria João Oliveira; Teresa Borges; Maria Helena Cardoso
Journal:  Acta Diabetol       Date:  2022-10-08       Impact factor: 4.087

2.  Search for a time- and cost-saving genetic testing strategy for maturity-onset diabetes of the young.

Authors:  Petra Dusatkova; Marketa Pavlikova; Lenka Elblova; Vladyslav Larionov; Klara Vesela; Katerina Kolarova; Zdenek Sumnik; Jan Lebl; Stepanka Pruhova
Journal:  Acta Diabetol       Date:  2022-06-23       Impact factor: 4.087

3.  Glucokinase (GCK) mutations and their characterization in MODY2 children of southern Italy.

Authors:  Marina Capuano; Carmen Maria Garcia-Herrero; Nadia Tinto; Carla Carluccio; Valentina Capobianco; Iolanda Coto; Arturo Cola; Dario Iafusco; Adriana Franzese; Adriana Zagari; Maria Angeles Navas; Lucia Sacchetti
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

4.  Identification and functional characterisation of novel glucokinase mutations causing maturity-onset diabetes of the young in Slovakia.

Authors:  Lucia Valentínová; Nicola L Beer; Juraj Staník; Nicholas D Tribble; Martijn van de Bunt; Miroslava Hučková; Amy Barrett; Iwar Klimeš; Daniela Gašperíková; Anna L Gloyn
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

5.  Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications.

Authors:  Rochelle N Naylor; Priya M John; Aaron N Winn; David Carmody; Siri Atma W Greeley; Louis H Philipson; Graeme I Bell; Elbert S Huang
Journal:  Diabetes Care       Date:  2013-09-11       Impact factor: 19.112

6.  Evidence-based tailoring of bioinformatics approaches to optimize methods that predict the effects of nonsynonymous amino acid substitutions in glucokinase.

Authors:  Daniela Šimčíková; Lucie Kocková; Kateřina Vackářová; Miroslav Těšínský; Petr Heneberg
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

7.  Dysmorphic Features, Frontal Cerebral Cavernoma, and Hyperglycemia in a Girl with a De Novo Deletion of 7.23 Mb in Region 7p13-p12.1.

Authors:  Gilberto Pérez López; Beatriz Villafuerte Quispe; María José Cabrejas Núñez; Luis Castaño; Raquel Barrio
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-04-07

8.  The Mutation Spectrum of Maturity Onset Diabetes of the Young (MODY)-Associated Genes among Western Siberia Patients.

Authors:  Dinara E Ivanoshchuk; Elena V Shakhtshneider; Oksana D Rymar; Alla K Ovsyannikova; Svetlana V Mikhailova; Veniamin S Fishman; Emil S Valeev; Pavel S Orlov; Mikhail I Voevoda
Journal:  J Pers Med       Date:  2021-01-18

9.  Chronic Mild Hyperglycemia in GCK-MODY Patients Does Not Increase Carotid Intima-Media Thickness.

Authors:  Stepanka Pruhova; Petra Dusatkova; Pavel J Kraml; Michal Kulich; Zdena Prochazkova; Jan Broz; Jaroslav Zikmund; Ondrej Cinek; Michal Andel; Oluf Pedersen; Torben Hansen; Jan Lebl
Journal:  Int J Endocrinol       Date:  2013-09-11       Impact factor: 3.257

10.  A De Novo Whole GCK Gene Deletion Not Detected by Gene Sequencing, in a Boy with Phenotypic GCK Insufficiency.

Authors:  N H Birkebæk; J S Sørensen; J Vikre-Jørgensen; P K A Jensen; O Pedersen; T Hansen
Journal:  Case Rep Genet       Date:  2011-10-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.